Sutro Biopharma Faces Nasdaq Delisting Warning

Ticker: STRO · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1382101

Sutro Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanySutro Biopharma, Inc. (STRO)
Form Type8-K
Filed DateJun 25, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: listing-standards, delisting-risk, compliance

TL;DR

Nasdaq says Sutro's stock price is too low, giving them until Dec 17 to fix it or get booted.

AI Summary

Sutro Biopharma, Inc. announced on June 20, 2025, that it received a notice from the Nasdaq Stock Market regarding its failure to meet the minimum bid price requirement for continued listing. The company has 180 calendar days, until December 17, 2025, to regain compliance by achieving a closing bid price of $1.00 or more for at least 10 consecutive business days.

Why It Matters

This notice indicates potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — Failure to meet the minimum bid price requirement poses a direct threat of delisting from a major stock exchange.

Key Numbers

  • 180 — calendar days (The period Sutro Biopharma has to regain compliance with Nasdaq's minimum bid price rule.)
  • $1.00 — minimum bid price (The target closing bid price Sutro Biopharma must achieve for 10 consecutive business days.)

Key Players & Entities

  • Sutro Biopharma, Inc. (company) — The company filing the report and receiving the notice.
  • Nasdaq Stock Market (company) — The exchange that issued the non-compliance notice.
  • June 20, 2025 (date) — The date the notice was received.
  • December 17, 2025 (date) — The deadline for Sutro Biopharma to regain compliance.
  • $1.00 (dollar_amount) — The minimum closing bid price required for compliance.

FAQ

What specific rule did Sutro Biopharma fail to meet according to Nasdaq?

Sutro Biopharma failed to meet the minimum bid price requirement for continued listing on the Nasdaq Stock Market.

What is the deadline for Sutro Biopharma to regain compliance?

The company has until December 17, 2025, to regain compliance.

What is the required closing bid price for compliance?

Sutro Biopharma must achieve a closing bid price of $1.00 or more.

For how many consecutive business days must the bid price requirement be met?

The closing bid price must be $1.00 or more for at least 10 consecutive business days.

What is the company's primary business as indicated by its SIC code?

The company's Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding SUTRO BIOPHARMA, INC. (STRO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.